A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
Naunyn-Schmiedeberg's Archives of Pharmacology · 2023
DOI: 10.1007/s00210-023-02465-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2023. Verfasst von Gizem Kayki-Mutlu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Ankara University, Ankara, Turkey. Hauptthemen laut MEDLINE: COVID-19, Biological Products. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsmedizin der Johannes Gutenberg-Universität Mainz.
Abstract (Originalsprache)
While new drug approvals by the U.S. Food and Drug Administration (FDA) had remained stable or even increased in the first 2 years of the COVID-19 pandemic, the 37 newly approved drugs in 2022 are considerably less than the 53 and 50 new drugs approved in 2020 and 2021, respectively, and less than the rolling 10-year average of 43. As in previous years of this annual review, we assign these new drugs to one of three levels of innovation: first drug against a condition (“first-in-indication”), first drug using a novel molecular mechanism (“first-in-class”), and “next-in-class,” i.e., a drug using an already exploited molecular mechanism. We identify two “first-in-indication” (ganaxolon and teplizumab), 20 (54%) “first-in-class,” and 17 (46%) “next-in-class” drugs. By treatment area, rare diseases and cancer drugs were once again the most prevalent (partly overlapping) therapeutic areas. Other continuing trends were the use of accelerated regulatory approval pathways and the reliance on biopharmaceuticals (biologics).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Pharmacy, Ankara University, Ankara, Turkey.
- Department of Pharmacology, Faculty of Pharmacy, Izmir Katip Celebi University, Izmir, Turkey.
- Department of Pharmacology, University Medical Center, Universitätsmedizin Mainz, Johannes Gutenberg University, Langenbeckstr. 1, 55118, Mainz, Germany.
- Department of Pharmacology, University Medical Center, Universitätsmedizin Mainz, Johannes Gutenberg University, Langenbeckstr. 1, 55118, Mainz, Germany. marmiche@uni-mainz.de.
Förderung
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Zitieren
APA
Kayki-Mutlu, G., Aksoyalp, Z. S., Wojnowski, L., & Michel, M. C. (2023). A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-023-02465-x
Vancouver
Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. Naunyn-Schmiedeberg's Archives of Pharmacology. 2023. doi:10.1007/s00210-023-02465-x
BibTeX
@article{KaykiMutlu2023,
author = {Kayki-Mutlu, Gizem and Aksoyalp, Zinnet Sevval and Wojnowski, Leszek and Michel, Martin C},
title = {A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2023},
doi = {10.1007/s00210-023-02465-x}
}
EUVIMED